AVEO Oncology
Latest round
- Series D
Last raised
- May 2007
Total raised
- $111M
Investors
- 13
About AVEO Oncology
AVEO Oncology is a US-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for cancer treatment.Founded in 2001 and headquartered in Boston, US, AVEO Oncology is dedicated to developing therapies for oncology.00 mn.AVEO Oncology is focused on developing and commercializing innovative oncology therapies, including its core product, FOTIVDA (tivozanib), which is FDA-approved for advanced renal cell carcinoma (RCC). FOTIVDA selectively inhibits vascular endothelial growth factor receptors, aiding in tumor growth inhibition.41 mn. The company is focused on launching new products aimed at enhancing treatment options for oncology, though specific release dates are not mentioned. Furthermore, AVEO aims to expand its reach into additional geographic markets, although the exact regions targeted for expansion are not specified.
Who invested in AVEO Oncology
13 investors across 3 rounds
See all investors in AVEO Oncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AVEO Oncology
Who invested in AVEO Oncology?
AVEO Oncology has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AVEO Oncology raised?
AVEO Oncology has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did AVEO Oncology last raise money?
AVEO Oncology's most recent round on record is a Series D, in May 2007.
What does AVEO Oncology do?
AVEO Oncology is a US-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for cancer treatment.
Where is AVEO Oncology headquartered?
AVEO Oncology is headquartered in Boston, US.
Which VCs invest in companies like AVEO Oncology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AVEO Oncology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like AVEO Oncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.